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 Summary
   The article is a review of current knowledge in the field of positron emission tomography and 
breast cancer diagnostics. It presents in a comprehensive way the physiological background of (18F) 
fluorodeoxyglucose (FDG) use in the diagnostics. The paper presents FDG study rules. The author 
discusses the indications for the PET studies in the field of breast cancer diagnostics, the current 
knowledge and some present prospects of PET development. 
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Positron emission tomography (PET) involves functional 
imaging of the whole body, the trunk or a selected organ 
(e.g. the brain, liver or heart) after intravenous administra-
tion of a radiopharmaceutical labeled with positron isoto-
pe. The P E T method is applied for imaging of tissues and 
organs utilizing the substances occurring physiologically 
in the organism (or their precursors), labeled with radio-
active elements with low atomic mass, emitting positrons 
as a result of their disintegration. After leaving the atom 
orbits, the positrons collide with negatively charged elec-
trons, which results in the annihilation phenomenon and 
emission of two quanta of gamma radiation of 511,9 keV 
energy, which is recorded by PET apparatus. Disintegrating 
fluorine isotope 18F is one of the components of fluorodeo-
xyglucose – FDG.
The use of fluorodeoxyglucose allows to visualize the tissu-
es demonstrating increased glucose demand. Because of the 
common metabolic pathway of 18 FDG and glucose up to 
the level of glucose phosphorylation, 18FDG falls into the 
“metabolic trap”.
As early as in the 1920’s-30’s, Warburg observed increased 
glucose demand presented by tumors. He also demonstra-
ted that „In tumor cells thirteen glucose molecules undergo 
„fermentation” and only one oxidation.” The above indicates 
manifold higher demand for this metabolite in most tumor 
tissues, including breast cancers.
Thus, PET, or more precisely PET/CT technique (as 90% of 
newly installed devices are hybrid scanners at present) is 
an examination with a potential to differentiate malignant 
tumor tissue from benign lesions. Its application in breast 
cancer diagnostics ranges from examinations of the primary 
tumors, through staging of the hyperplastic process, treat-
ment monitoring, to prediction of the course of the disease. 
Preparation of the patient 
•  The patient should be fasting (min. 6 h prior to the exami-
nation) but hydrated, exclusively with PURE mineral water
•  Serum glucose level should not exceed 150 mg%
•  After FDG administration, no physical exertion, talking, 
chewing gum allowed
•  The procedure should be performed with caution in 
patients with renal insufficiency
•  The patient brings:
 – 1 l still mineral water
 – A social security document 
 – Results of imaging diagnostics
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Diagnostics of primary lesions
The first results concerning the application of PET in 
breast cancer diagnostics were encouraging. Adler et 
al. [1] demon strated in a group of 124 patients with high 
risk of breast cancer a sensitivity of 97% and speci ficity 
of 100%. Their results were confirmed by the study by 
Utech et al. [2]  demonstrating 100% sensitivity and the 
same speci ficity in a group of 79 patients with breast can-
cer < 3 cm. However, further studies were not so optimis-
tic. PET sensitivity was found to be significantly reduced 
in tumors less than 1 cm in diameter. In the largest-scale 
study the sensitivity of detection for tumors < 1cm was 
57%, for tumors > 1 cm – 91%. We do not have cur rently 
any  representative data concerning the sensitivity, speci-
ficity and accuracy of PET/CT performed using the  latest 
 generation equipment in the preliminary diagnostics 
of breast cancers below 8 mm in diameter. Tumor size 
(> 10 mm) and low differentiation are two independent 
factors causing false negative results. No effect of such fac-
tors as: the patient’s age, tumor type, estrogen and proges-
terone receptors, parenchyma density, metastases to senti-
nel lymph node and distant metastases, as well as single or 
multiple primary lesions has been noted. 
There are hopes for overcoming the lesion size barrier owing 
to new equipment combining a mammograph with PET and 
fusion images combining the functional images provided by 
PET and morphological images obtained by mammography. 
This technique is referred to as PEM (positron emission 
mammography). The results obtained with this method are 
excellent: sensitivity 91%, specificity 93%, PPV 95%, NPV 
88%, accuracy 92%, if assessed in combination with clinical 
and mammographic data – 94.9% [3]. It should be remem-
bered that these figures concern only the assessment of 
the mammary gland, and not the whole body, as it is the 
case with classic PET technique. However, in diagnostics of 
small diameter lesions, and consequently, at early stages of 
progression, a technique of this type can become very use-
ful in future, enabling to differentiate benign and malignant 
lesions on the basis of metabolic activity at the site of an 
“abnormality” revealed by mammography. 
Staging of the disease
In assessment of post-augmentation mammoplasty condi-
tions, PET belongs to the leading diagnostic techniques. 
Such infrequent cases, whose interpretation is difficult for 
classic diagnostic methods, have been classified correctly 
by functional imaging utilizing [4, 5]. Staging of the disease 
and diagnostics of relapses or distant metastases is the area 
in which PET technique has been unquestionably success-
ful since its introduction to the medical market. The results 
obtained with PET and FDG are significantly superior to 
those obtained with classic imaging techniques. For instance: 
PET and CT of the thorax were compared in a group of 73 
patients with breast cancer relapses and metastases.
Method sensitivity specificity
PET:   85%  90%
CT:   50%  85%
In 33% of patients, PET results led to a change in staging 
and treatment method.
In another group of patients – 39 subjects with elevated 
tumor markers, PET diagnosed relapses correctly in 94% of 
cases, in contrast to conventional imaging techniques (CT 
and MRI) – 18%. 
In assessment of bone metastases, PET FDG detects lesions 
of osteolytic character, overlooked by standard bone scin-
tigraphy, whereas it may not visualize the lesions of osteo-
blastic character detected by BS. The overall sensi tivity 
and specificity of PET utilizing FDG and classic BS are 
comparable, but it should be emphasized that these two 
techniques are complementary to each other [6]. PET with 
sodium fluoride (18 F)NaF seems to be a solution. The sen-
sitivity of this technique approximates 100% with similar 
specificity [7].
The accuracy of PET and sentinel node scintigraphy 
are similar. PET inadequately identifies the number of 
involved lymph nodes, but it visualizes the mediastinal 
lymph nodes generally inaccessible with other techniques. 
Micro metastases cannot be visualized by PET but their 
significance in clinical practice has not been determined. 
In the largest-scale study in a group of 124 patients, PET 
visualized correctly metastases to the lymphatic system in 
100%, ie. 44 patients. In another study, sensitivity, speci-
ficity and accuracy reached, respectively, 85%, 91% and 
89% [8, 9].
PET technique utilizing FDG has a significant impact 
on staging, affecting it in 36% of cases, as well as on the 
manage ment of patients with breast cancer, which is 
 modified in 56% [10]. In another study, in comparison with 
classic imaging modalities, PET led to staging alteration in 
67% (43% – increase, 24% – decrease). The management of 
the patients was modified in 32% of cases [11].
Assessment of the therapy
Another application, finding increasing support in scien-
tific evidence, is the assessment of efficacy of the adopted 
therapeutic regimen. Significant decreases of metabolic 
activity (to 72 %) were observed in the group of patients 
responding to treatment, in contrast to no such effect in 
the group of non-responders. The changes were visible as 
early as after the first course of treatment [12]. In  another 
study, a decrease by 28% after the first cycle and by 46% 
after the second one was reported in „responders”. The 
conclusions from the latter study provide strong evi-
dence that PET FDG can predict the effectiveness even 
after one chemotherapy cycle [13, 14, 15]. The decrease 
of metabolic activity by 55% in comparison with baseline 
values differentiated  „responders” from „non-responders” 
with 100% sensitivity, 85% specificity and 88% accuracy 
[16]. Monitoring breast cancer patients with PET seems 
to be more accurate and reliable than classic imaging 
modalities. 
Classic imaging methods (X-ray mammography, US, CT, MRI 
and bone scans) were compared with PET in a study group 
of 62 patients after surgical breast cancer resection [17].
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 Sensitivity   Specificity  NPV PPV Accuracy
PET 97% 82% 92% 87%  90%
CI  84% 60% 75% 73%  74%
In meta-analysis of 16 out of 28 studies, including 
808 breast cancer patients, the obtained sensitivity 
was 92.7%, and specificity 81.6% for PET FDG applied 
in assessment of tumor relapse and metastases [18]. 
Because of false positive results of PET with FDG used, 
due to inflammatory conditions or other non-neoplastic 
changes enhancing focally glucose metabolism, studies 
concerning utilization of other markers are presently 
under way. Promising results have been obtained with 
18F fluorothymidine as a marker of enhanced DNA rep-
lication process. In 8 out of 10 patients with breast can-
cer, 18F-FLT PET visualized correctly the presence of a 
malignant process [19]. There were no additional foci of 
marker metabolism. In another study, 13 out of 14 pri-
mary breast tumors and 7 out of 8 metastases to axillary 
lymph nodes were diagnosed correctly using 18F-FLT 
PET [20]. 
Summing up the presented study, the following areas of 
application can be indicated for PET technique in breast 
cancer diagnostics:
1.  Screening in the group of patients with mammographi-
cally „dense” mammary glands (limited area, PEM).
2.  Screening in the group of patients with implants and 
after reconstruction surgery (limited area, PEM).
3.  „Lymph node staging” in patients with high probability of 
thoracic lymph nodes involvement (limited area).
4.  Staging in patients with high risk of metastatic lesions 
(whole-body PET).
5.  Metabolic characteristics of suspicious lesions in conven-
tional diagnostics (whole-body PET).
6.  Re-staging in the group of patients in which numerous re pe-
ated conventional tests are necessary (whole-body PET).
7.  Monitoring chemotherapy effects in order to determine 
the patient’s response to treatment and assess its effects 
(limited or whole-body PET).
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